Drug updated on 11/10/2023
|Tablet (oral; trifluridine/ tipiracil: 15 mg/6.14 mg, 20 mg/8.19 mg)
|Ongoing and Completed Studies
- For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
- For the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
Product Monograph / Prescribing Information
|Lonsurf (trifluridine and tipiracil) Prescribing Information.
Systematic Reviews / Meta-Analyses
|The effect of trifluridine/tipiracil for patients with heavily pretreated metastatic gastric cancer.
|Final clinical guidance report: trifluridine-tipiracil (Lonsurf) for gastric cancer.
|Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.
|Journal of Cancer Research and Clinical Oncology
|Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials.
|Journal of Chemotherapy
|Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
|International Journal of Colorectal Disease
|Final clinical guidance report: trifluridine-tipiracil (Lonsurf) for metastatic colorectal cancer (resubmission).
|A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
|Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.